Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Targeted Anticancer Therapies Congress 2024, 26-28 February, Paris, France

20 Feb 2024

Lugano, Switzerland, 19 February 2024 – The ESMO Targeted Anticancer Therapies Congress 2024 is the annual multi-stakeholder meeting that focuses on the development of novel anticancer therapies and how this can transform the current knowledge and impact clinical care. This event brings together various experts in the early drug development arena, including investigators from academia, investor and regulatory bodies, as well as translational scientists.

The event will be held in Paris, France, between 26-28 February.

New this year

  • Four new special sessions will enrich this year’s scientific programme, with international speakers from the pharmaceutical industry addressing methodological and regulatory challenges in the development and implementation of innovative cancer therapeutics.
    Related content: Session on 26 February, 13:45-15:15 CET; Sessions on 27 February, 11:15-12:45 CET and 13:45-15:15 CET; Session on 28 February, 13:30-15:00 CET

Programme highlights

  • The role of artificial intelligence, machine learning, and digital technology in early phase research: From uncovering new immunotherapy targets with clinical potential to unveiling new potential targeted therapies 
    Related content: 1O, 2P, 4P, 5P and session on 27 February, 8:00-8:45 CET
  • Novel perspectives on antibody-drug conjugates: new targets, linkers, payloads and combination with other agents 
    Related content: Session on 28 February, 09:15-10:45 CET
  • ctDNA as promising biomarker to predict the patients’ response to treatment and guide experimental therapeutics in phase I trials
    Related content: 85O, 86O, Session on 27 February, 09:15-10:45 CET

Award keynote lectures

The results of more than 110 studies from various parts of the world will be presented and published online as a supplement to ESMO Open. The abstract titles can be viewed through the online programme.

Press accreditation

ESMO welcomes press representatives working for recognised press outlets interested in obtaining information and reporting on cancer issues, upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities. To apply for press accreditation, please fill out the form available here. Requests for press accreditation should be sent by Friday, 23 February. Please be kindly informed that onsite press accreditation will not be available.

Further information

ESMO Press Office

Notes to editors

Please make sure to use the official name of the meeting in your reports: ESMO TAT 2024 and the official congress hashtag #ESMOTAT24. Follow it to stay up to date and use it to take part in the conversation on X (Twitter), LinkedIn, Instagram, Facebook

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.